330 confirmed Bundibugyo Ebola cases and 49 deaths had been recorded in Congo by May 31, with 116 more suspected cases under investigation and a few infections also reported in Uganda.
Aid cuts slowed surveillance and delayed detection, while stockpiled Ebola tools proved largely useless because vaccines and approved antibody treatments were built for the Zaire strain, not Bundibugyo.
Researchers say Bundibugyo appears less lethal than Zaire Ebola but may keep patients infectious longer, a combination that could prolong transmission even if the case-fatality rate stays lower.
MBP134 and a Regeneron antibody cocktail are set for clinical testing during the outbreak, and obeldesivir is also under consideration, but no Bundibugyo-specific vaccine is ready for deployment.
WHO estimates a tweaked Ervebo-based vaccine could take 7 to 9 months to reach human trials, leaving supportive care and outbreak control as the main tools while scientists hunt the virus's animal reservoir.
Can experimental drugs stop a rare Ebola outbreak raging through an active conflict zone?
Why were we unprepared for an Ebola strain that was discovered nearly two decades ago?
Bundibugyo Ebola Outbreak 2026: Over 1,000 Cases, No Vaccine, and the Struggle for Containment in Central Africa
Overview
The 2026 Bundibugyo Ebola outbreak is a major and evolving public health crisis, with significant uncertainty about how many people are infected and how far the disease has spread. This lack of clear data makes it hard to understand the outbreak’s true scale and complicates efforts to contain it. Effective response depends on close cooperation with local communities and leaders, but mistrust and resistance remain big challenges. Without strong community engagement, it is much harder to control the virus, highlighting the urgent need for trust and collaboration to manage the outbreak successfully.